Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer

Journal of Clinical Oncology

Volumn 24, Issue 30, 2006, Pages 4840-4847

  Socinski, Mark A ^a   Weissman, Charles ^a   Hart, Lowell L ^a   Beck, J Thaddeus ^a   Choksi, Janak K ^a   Hanson, John P ^a   Prager, Diane ^a   Monberg, Matthew J ^a   Ye, Zhishen ^a   Obasaju, Coleman K ^a  

^a UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BRAIN TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; VOMITING; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SMALL CELL CARCINOMA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; CISPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33750620855     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.7016     Document Type: Article

References (40)

1. American Cancer Society: Cancer facts and figures 2006. http://www.cancer.org/docroot/STT/ content/STT_1x_Cancer_Facts__Figures_2006.asp
2. Gillenwater H, Socinski MA: Extensive stage small cell lung cancer, in Detterbeck F, Rivera M, Socinski M (eds): Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA, Saunders, 2001, pp 360-376
3. Morris D, Socinski MA, Detterbeck F: Limited stage small cell lung cancer, in Detterbeck F, Rivera M, Socinski M (eds): Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA, Saunders, 2001, pp 341-359
4. Auperin A, Arriagada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476-484, 1999
5. Fried DB, Morris DE, Poole C, et al: Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837-4845, 2004
6. Kies MS, Mira JG, Crowley JJ, et al: Multimodal therapy for limited small-cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: A Southwest Oncology Group Study. J Clin Oncol 5:592-600, 1987
7. Perry MC, Eaton WL, Propert KJ, et al: Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316:912-918, 1987
8. Turrisi AT 3rd, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
9. Niell H, Herndon J, Miller A: Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF inpatients with extensive stage small cell lung cancer (ED-SCLC). Proc Am Soc Clin Oncol 21:293a, 2002 (abstr 1169)
10. Schiller JH, Adak S, Cella D, et al: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114-2122, 2001
11. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
12. Hanna N, Einhorn L, Sandler A, et al: Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). J Clin Oncol 24:622s, 2005 (suppl; abstr LBA7004)
13. Eckardt J, von Pawel J, Manikhas G, et al: Comparable activity with oral topotecan/cisplatin (TC) and IV etoposide/cisplatin (PE) as treatment for chemotherapy-naïve patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Final results of a randomized phase III trial (389). J Clin Oncol 24:621s, 2005 (suppl; abstr 7003)
14. Adjei AA: Pemetrexed (Alimta): A novel multitargeted antifolate agent. Expert Rev Anticancer Ther 3:145-156, 2003
15. Adjei AA: Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 10:4276S-4280S, 2004
16. Mendelsohn LG, Shih C, Chen VJ, et al: Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 26:42-47, 1999
17. Schultz RM, Chen VJ, Bewley JR, et al: Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 26:68-73, 1999
18. Clarke SJ, Abratt R, Goedhals L, et al: Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13:737-741, 2002
19. Manegold C, Gatzemeier U, von Pawel J, et al: Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol 11:435-440, 2000
20. Rusthoven JJ, Eisenhauer E, Butts C, et al: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study - National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194, 1999 (abstr)
21. Scagliotti GV, Kortsik C, Dark GG, et al: Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial. Clin Cancer Res 11:690-696, 2005
22. Shepherd FA, Dancey J, Arnold A, et al: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92:595-600, 2001
23. Smit EF, Mattson K, von Pawel J, et al: ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: A phase II study. Ann Oncol 14:455-460, 2003
24. Vogelzang NJ, Rusthoven J J, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003
25. Zinner RG, Fossella FV, Gladish GW, et al: Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104:2449-2456, 2005
26. Cripps C, Burnell M, Jolivet J, et al: Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study. Ann Oncol 10:1175-1179, 1999
27. Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol 29:49-53, 2002
28. O'Shaughnessy JA, Clark RS, Blum JL, et al: Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 6:143-149, 2005
29. Paz-Ares L, Ciruelos E, Garcia-Carbonero R, et al: Pemetrexed in bladder, head and neck, and cervical cancers. Semin Oncol 29:69-75, 2002
30. Spielmann M, Martin M, Namer M, et al: Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: An interim analysis. Clin Breast Cancer 2:47-51, 2001
31. Thodtmann R, Sauter T, Weinknecht S, et al: A phase II trial of pemetrexed in patients with metastatic renal cancer. Invest New Drugs 21:353-358, 2003
32. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
33. Niyikiza C, Baker SD, Seitz DE, et al: Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1.545-552, 2002
34. Therasse P, Arbuck S, Eisenhauer E: New guidelines to evaluate the response to treatement in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
35. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
36. Kaplan E, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53: 457-481, 1958
37. Greco FA, Thompson DS, Morrissey LH, et al: Paclitaxel/carboplatin/ etoposide versus paclitaxel/ topotecan for extensive-stage small cell lung cancer: A Minnie Pearl Cancer Res Network randomized, prospective phase II trial. Oncologist 10:728-733, 2005
38. Okamoto H, Watanabe K, Kunikane H, et al: Randomized phase III trial of carboplatin(C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702. J Clin Oncol 24:623s, 2005 (suppl; abstr LBA7010)
39. Socinski MA: Pemetrexed (Alimta) in small cell lung cancer. Semin Oncol 32:S1-S4, 2005
40. Vokes E, Szeto L, Mauer A: A phase I trial of pemetrexed + chest radiotherapy in patients with advanced or metastatic non-small cell lung cancer or esophageal cancer. Lung Cancer 41:S89, 2003 (abstr)